Summit Therapeutics Partner Akeso Announced Sunday, Phase 3 HARMONi-GI1 Trial Met Overall Survival Superiority Endpoint For Ivonescimab + Chemotherapy Vs. Durvalumab + Chemotherapy In First-Line Advanced Biliary Tract Cancer

Loading news article.

Summit Therapeutics Partner Akeso Announced Sunday, Phase 3 HARMONi-GI1 Trial Met Overall Survival Superiority Endpoint For Ivonescimab + Chemotherapy Vs. Durvalumab + Chemotherapy In First-Line Advanced Biliary Tract Cancer | WAPE

Summit Therapeutics Partner Akeso Announced Sunday, Phase 3 HARMONi-GI1 Trial Met Overall Survival Superiority Endpoint For Ivonescimab + Chemotherapy Vs. Durvalumab + Chemotherapy In First-Line Advanced Biliary Tract Cancer

Article summary

Related companies

Comments —